The aforementioned AMPARs downstream of the NMDARs antagonized by ketamine are responsible for activation of BDNF-TrkB signaling, which has already been implicated both in the neurobiology of depression and the neuropharmacological mechanisms behind existing depression treatments, as discussed earlier [1]. Here, NTRK2 is linked to depressive disorder.